Yu-Fen Lin1, Benjamin P Chen1, Wende Li2, Zoltan Perko3, Yi Wang2, Mauro Testa2, Robert Schneider2, Hsaio-Ming Lu2, Leo E Gerweck2. 1. Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. 2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Radiation, Science and Technology, Delft University of Technology, Delft, The Netherlands.
Abstract
PURPOSE: Variations in the radiosensitivity of tumor cells within and between tumors impact tumor response to radiation, including the dose required to achieve permanent local tumor control. The increased expression of DNA-PKcs, a key component of a major DNA damage repair pathway in tumors treated by radiation, suggests that DNA-PKcs-dependent repair is likely a cause of tumor cell radioresistance. This study evaluates the relative biological effect of spread-out Bragg-peak protons in DNA-PKcs-deficient cells and the same cells transfected with a functional DNA-PKcs gene. MATERIALS AND METHODS: A cloned radiation-sensitive DNA-PKcs-deficient tumor line and its DNA-PKcs-transfected resistant counterpart were used in this study. The presence of functional DNA-PKcs was evaluated by DNA-PKcs autophosphorylation. Cells to be proton irradiated or x-irradiated were obtained from the same single cell suspension and dilution series to maximize precision. Cells were concurrently exposed to 6-MV x-rays or mid 137-MeV spread-out Bragg peak protons and cultured for colony formation. RESULTS: The surviving fraction data were well fit by the linear-quadratic model for each of 8 survival curves. The results suggest that the relative biological effectiveness of mid spread-out Bragg peak protons is approximately 6% higher in DNA-PKcs-mediated resistant tumor cells than in their DNA-PKcs-deficient and radiation-sensitive counterpart. CONCLUSION: DNA-PKcs-dependent repair of radiation damage is less capable of repairing mid spread-out Bragg peak proton lesions than photon-induced lesions, suggesting protons may be more efficient at sterilizing DNA-PKcs-expressing cells that are enriched in tumors treated by conventional fractionated dose x-irradiation.
PURPOSE: Variations in the radiosensitivity of tumor cells within and between tumors impact tumor response to radiation, including the dose required to achieve permanent local tumor control. The increased expression of DNA-PKcs, a key component of a major DNA damage repair pathway in tumors treated by radiation, suggests that DNA-PKcs-dependent repair is likely a cause of tumor cell radioresistance. This study evaluates the relative biological effect of spread-out Bragg-peak protons in DNA-PKcs-deficient cells and the same cells transfected with a functional DNA-PKcs gene. MATERIALS AND METHODS: A cloned radiation-sensitive DNA-PKcs-deficient tumor line and its DNA-PKcs-transfected resistant counterpart were used in this study. The presence of functional DNA-PKcs was evaluated by DNA-PKcs autophosphorylation. Cells to be proton irradiated or x-irradiated were obtained from the same single cell suspension and dilution series to maximize precision. Cells were concurrently exposed to 6-MV x-rays or mid 137-MeV spread-out Bragg peak protons and cultured for colony formation. RESULTS: The surviving fraction data were well fit by the linear-quadratic model for each of 8 survival curves. The results suggest that the relative biological effectiveness of mid spread-out Bragg peak protons is approximately 6% higher in DNA-PKcs-mediated resistant tumor cells than in their DNA-PKcs-deficient and radiation-sensitive counterpart. CONCLUSION: DNA-PKcs-dependent repair of radiation damage is less capable of repairing mid spread-out Bragg peak proton lesions than photon-induced lesions, suggesting protons may be more efficient at sterilizing DNA-PKcs-expressing cells that are enriched in tumors treated by conventional fractionated dose x-irradiation.
Authors: Kazuhiko Ogawa; Yves Boucher; Satoshi Kashiwagi; Dai Fukumura; David Chen; Leo E Gerweck Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Andrea O Fontana; Marc A Augsburger; Nicole Grosse; Matthias Guckenberger; Anthony J Lomax; Alessandro A Sartori; Martin N Pruschy Journal: Radiother Oncol Date: 2015-08-25 Impact factor: 6.280
Authors: Stefan C Genet; Junko Maeda; Hiroshi Fujisawa; Charles R Yurkon; Yoshihiro Fujii; Ashley M Romero; Paula C Genik; Akira Fujimori; Hisashi Kitamura; Takamitsu A Kato Journal: Oncol Rep Date: 2012-08-22 Impact factor: 3.906